-
Kangtai Biotech won the "2021 China Biomedical Enterprises Top 10"
Time of Update: 2022-10-02
On July 12, the Expert Committee of China's Top 100 Pharmaceutical Industry released the "2021 China Pharmaceutical Industry Top 100 Series List". Shenzhen Kangtai Biological Products Co. , Ltd. (sto
-
Notice for Public Comment on the Quantitative Methodological Guidelines for Extrapolating Adult Drug Data to Pediatric Populations (Draft for Solicitation of Comments).
Time of Update: 2022-10-02
Drug Evaluation Center of the State Drug Administration September 19, 2022 Related Attachments serial number The attachment name 1 Quantitative Methodological Guidelines for Extrapolating Adult Drug Data to Pediatric Populations (Draft for Comment).
-
Relying on a listed oncology drug, the science and technology innovation board pharmaceutical company successfully opened the door to profitability
Time of Update: 2022-10-02
Recently, the pharmaceutical companies listed on the Science and Technology Innovation Board have basically revealed the semi-annual report card of 2022, and nearly 80% of Biotech is still in a state
-
The good is coming, and the chronic disease medical insurance is fully opened to the designated pharmacies!
Time of Update: 2022-10-02
03 According to local conditions, improve the ability to absorb customers For pharmacies, chronic disease drug buyers have a high customer list, a large number of purchases, high sales contribution, chronic disease drugs are considered to be a variety of suckers, on the other hand, consumers have more selectivity in drug purchase channels, strong brand dependence, long taking cycle, for the consumption characteristics of such people, how should pharmacies formulate operational strategies?
-
Change of deputy general manager of pharmaceutical company: 3 deputy general managers of the company leave within 1 day!
Time of Update: 2022-10-02
In addition, on the evening of July 1, Xinhua Pharmaceutical issued an announcement that Mr. Du Deping applied to resign from all positions of the company's directors, general managers, professional committees under the board of directors and subsidiaries of the company due to job changes.
-
Behind the signing of the contract between Huahai and Pfizer for the commissioned production of new coronavirus drugs, the MAH system dividend releases new opportunities for development
Time of Update: 2022-10-02
MAH policy dividends release new opportunities for development Behind the production commission cooperation between Huahai Pharmaceutical and Pfizer, it also reflects that the dividends of China's drug marketing authorization holder (MAH) system are being released.
-
The "14th Five-Year Plan" elderly population will exceed 300 million How to ensure that the "elderly have support"?
Time of Update: 2022-10-02
2 billion yuan to support 84 regions to carry out the improvement of basic old-age services in home communities, and in these pilot and promotion actions, promote the exploration of the formation of family old-age beds, meals, baths, cleaning, medical assistance, walking assistance, emergency "six assistance" services, visiting care, mutual assistance for the elderly and other service models to meet the diversified old-age needs.
-
Notice on the public solicitation of opinions on the Technical Guidelines for the Clinical Development of Anti-tumor Antibody Conjugated Drugs
Time of Update: 2022-10-02
docx 2The feedback form of the "Technical Guidelines for the Clinical Development of Anti-tumor Antibody Conjugated Drugs (Draft for Comments)" .
docx 2The feedback form of the "Technical Guidelines for the Clinical Development of Anti-tumor Antibody Conjugated Drugs (Draft for Comments)" .
-
In the first half of the year, the R&D expenditure of 5 traditional Chinese medicine enterprises exceeded 200 million
Time of Update: 2022-10-02
It is worth mentioning that in the first half of the year, under the background of the growth of R&D investment, Kangyuan Pharmaceutical accelerated the establishment and research and development of pediatric, cardiovascular, elderly and metabolic disease drugs, expanded new clinical fields, and strengthened the research on the cultivation of key medical insurance or basic drugs in traditional Chinese medicine.
-
Qinghai and 59,000 medical institutions across the country opened direct settlement business for medical treatment in different places
Time of Update: 2022-10-02
In order to meet the needs of insured personnel in Qinghai Province for medical treatment outside the province and reduce their pressure to run errands and advance funds, as early as 2009, Qinghai opened a medical expense reimbursement business in the Shanghai Pudong New Area Medical Insurance Center; In 2013, the direct settlement business of medical and hospitalization expenses for provincial-level employees in Xi'an was opened.
-
Yiling Pharmaceutical Co., Ltd. was ranked as one of the top 20 most competitive pharmaceutical companies in China in 2022
Time of Update: 2022-10-02
Recently, under the guidance of the China Pharmaceutical Enterprise Management Association, the results of the "2022 China Top 20 Pharmaceutical Listed Companies Competitiveness" jointly launched by E drug manager Rong Media and Jun Consulting were announced.
-
Proprietary Chinese medicine collection is coming! Analysis of the competition pattern of overlapping varieties of regional collection and national harvesting!
Time of Update: 2022-10-02
On September 9, Hubei Pharmaceutical Price and Bidding Procurement Management Service Network released the "National Proprietary Chinese Medicine Alliance Procurement Announcement (No. 1 of 2022)". T
-
China will carry out special activities for the health promotion of traditional Chinese medicine in the Healthy China Action
Time of Update: 2022-10-01
The Healthy China Action Promotion Office, the General Office of the National Health Commission and the Office of the State Administration of Traditional Chinese Medicine recently jointly issued the
-
Recently, a large number of pharmaceutical companies have had large transactions, and 2 pharmaceutical companies have accumulated 11 transactions in the past three months
Time of Update: 2022-10-01
According to further statistics, there have been 11 block transactions in the stock in the past three months, with a total transaction amount of 119 million yuan.
-
The Chinese medicine industry has long-term investment value, and these tracks have great potential
Time of Update: 2022-10-01
Traditional Chinese medicine OTC TCM OTC has the characteristics of strong policy immunity, small risk of cost control and price reduction, and because the main sales channel is at the retail end rather than public medical institutions, it has higher price maintenance capabilities, so the industry generally believes that the future expansion of the industry can be expected.
-
Shouzheng innovation, Chinese medicine "go out" into the fast lane
Time of Update: 2022-10-01
Scientific and technological support leads the development of innovation At the meeting, Li Yu, director of the Department of Science and Technology of the State Administration of Traditional Chinese Medicine, pointed out that in the past ten years, through clinical and mechanism research, traditional Chinese medicine has made important progress in the treatment of ischemic stroke, non-small cell lung cancer, diabetes, COPD and a series of major diseases, common and multiple diseases.
-
11 non-medical insurance, a number of key monitoring varieties, to meet the "eight provinces and two regions" collection
Time of Update: 2022-10-01
The second batch was led by Heilongjiang, and Qinghai and Guizhou were added to the first batch of provinces participating in the procurement of quantity, forming "eight provinces and two regions", 21 varieties entered the collection, a total of 145 pharmaceutical companies participated, and finally 14 pharmaceutical companies selected 16 product specifications, of which the highest price reduction was 92.
-
National medical insurance cross-provincial direct settlement of medical service information released
Time of Update: 2022-10-01
pharmacies Third, the national medical insurance service platform APP off-site medical settlement related query function has been further expanded In order to facilitate the insured to directly settle the treatment costs related to 5 kinds of outpatient chronic diseases in different places across provinces, the national medical insurance service platform APP has added query functions such as inter-provincial outpatient chronic disease notifications.
-
The National Medical Security Bureau carried out special treatment of oral implant prices
Time of Update: 2022-10-01
"A toothache is not a disease, it hurts really bad. " Some time ago, due to dental problems, Yang Heping, a retired worker living in Xicheng District of Beijing, came to the nearby stomatological hos
-
Under the favorable policy, domestic pharmaceutical companies are constantly increasing their attention to children's drugs!
Time of Update: 2022-10-01
Due to the difficulty of children's clinical research, in China, children's drugs have always had the "four less" situation of few varieties, few dosage forms, few specifications and fewer special dru
